Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 Plus Azacitidine With TBF Conditioning in High-risk or Relapsed/Refractory Acute Leukemia and MDS
NCT07562568Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zeprumetostat in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic neoplasms (MDS) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Cumulative incidence of relapse at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic neoplasms (MDS)
Beyond the preview
Go deeper on NCT07562568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562568.